Contract Research Organization WCCT Global Announces Continued Success in Japanese Bridging Clinical Trials - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Contract Research Organization WCCT Global Announces Continued Success in Japanese Bridging Clinical Trials Japanese bridging clinical trial success has been achieved by WCCT Global Full Service CRO


Contract Research Organization WCCT Global Announces Continued Success in Japanese Bridging Clinical Trials

Japanese bridging clinical trial success has been achieved by WCCT Global Full Service CRO

PR Newswire

COSTA MESA, Calif., Jan. 31, 2014 /PRNewswire-iReach/ -- WCCT Global, a full service CRO headquartered in Southern California announced today the overwhelming success of recruiting and completing a difficult Japanese bridging clinical trial. WCCT Global has been recognized as an industry leader when it comes to ethno bridging studies, specifically focused on Japanese population groups. Their process for recruiting and retaining the Japanese volunteers has set the industry standard for U.S. based Japanese bridging clinical research. The most recent study required WCCT Global to screen 115 first generation Japanese volunteers which was done successfully. The goal for this study was to enroll 68 first generation Japanese into the study but WCCT Global was able to surpass that amount and enroll 83 volunteers. This over-enrollment is attributed to WCCT Global's targeted recruitment methods and outreach to the Japanese community in Southern California to spark interest about clinical trial participation. WCCT Global has a Japanese call line so when potential volunteers call their facility, they are able to speak to their in-house fluent Japanese recruitment specialist who creates a seamless process to give all study information and conduct prescreening in the Japanese language.

(Photo: http://photos.prnewswire.com/prnh/20140131/MN56589)

Edward Kim, WCCT Global's Executive Director of Early Clinical Development stated, "I'm excited to be able to share such amazing news about our recruitment and screening efforts. Our ability to exceed enrollment by more than 20% for this study is a testament to WCCT Global's commitment to patient recruitment and retention efforts." With the increase of therapies being created by Japanese sponsors wanting to be in the U.S market, choosing an experienced full service CRO is crucial to the outcome of the study. WCCT Global will continue to assist Japanese sponsors reach their goals in the 2014 and beyond.

More about WCCT Global:

WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, "With compassion for people, we strive for tomorrow's therapies to be available today" truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.

If you would like to request information about how WCCT Global can assist your organization with a clinical study, please CLICK HERE

Media Contact: Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE WCCT Global

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here